Leitlinien, Literatur und Fachgesellschaften

• Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. CA Cancer J Clin. 2024 Jul-Aug;74(4):359-367. doi: 10.3322/caac.21840. Epub 2024 Apr 29. PMID: 38685134
• Diagnostic issues in neuroendocrine neoplasms of the lung. Kasajima A, Klöppel G. Pathologie (Heidelb). 2024 Oct 2. English. doi: 10.1007/s00292-024-01360-3. Epub ahead of print. PMID: 39356330
• The road ahead: a brief guide to navigating the 2022 WHO classification of endocrine and neuroendocrine tumours. Juhlin CC. J Clin Pathol. 2024 Jul 9:jcp-2023-209060. doi: 10.1136/jcp-2023-209060. Epub ahead of print. PMID: 38981664
• Aktuelle WHO-Klassifikation (2022) neuroendokriner Neoplasien [Current WHO classification (2022) of neuroendocrine neoplasms]. Buchstab O, Knösel T. Radiologie (Heidelb). 2024 Jul;64(7):531-535. German. doi: 10.1007/s00117-024-01295-z. Epub 2024 Apr 15. PMID: 38622292
• Changes in categorization or nomenclature within neuroendocrine tumors. Vocino Trucco G, Volante M. Endocr Relat Cancer. 2024 Jun 13;31(8):e240004. doi: 10.1530/ERC-24-0004. PMID: 38776393
• Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project. Mathian É, Drouet Y, Sexton-Oates A, Papotti MG, Pelosi G, Vignaud JM, Brcic L, Mansuet-Lupo A, Damiola F, Altun C, Berthet JP, Fournier CB, Brustugun OT, Centonze G, Chalabreysse L, de Montpréville VT, di Micco CM, Fadel E, Gadot N, Graziano P, Hofman P, Hofman V, Lacomme S, Lund-Iversen M, Mangiante L, Milione M, Muscarella LA, Perrin C, Planchard G, Popper H, Rousseau N, Roz L, Sabella G, Tabone-Eglinger S, Voegele C, Volante M, Walter T, Dingemans AM, Moonen L, Speel EJ, Derks J, Girard N, Chen L, Alcala N, Fernandez-Cuesta L, Lantuejoul S, Foll M. ESMO Open. 2024 Jun;9(6):103591. doi: 10.1016/j.esmoop.2024.103591. Epub 2024 Jun 14. PMID: 38878324
• Expanding Role of Gastroenterology in the Staging of Digestive Neuroendocrine Tumors: Updates From the American Joint Committee on Cancer Version 9 Cancer Staging System. Ge PS, Shi C, Asare E, Washington MK, O'Toole D; American Joint Committee on Cancer Expert Panel on Neuroendocrine Tumors. Clin Gastroenterol Hepatol. 2024 Mar;22(3):448-451. doi: 10.1016/j.cgh.2023.10.033. Epub 2023 Dec 5. PMID: 38056801
• Updates on lung neuroendocrine neoplasm classification. Vocino Trucco G, Righi L, Volante M, Papotti M. Histopathology. 2024 Jan;84(1):67-85. doi: 10.1111/his.15058. Epub 2023 Oct 4. PMID: 37794655

• Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L. Endocr Pathol. 2022 Mar;33(1):197-227. doi: 10.1007/s12022-022-09705-5. Epub 2022 Mar 13. PMID: 35285003
• Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Endocr Pathol. 2022 Mar;33(1):115-154. doi: 10.1007/s12022-022-09708-2. Epub 2022 Mar 16. PMID: 35294740
• The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD. J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20. PMID: 34808341

• Lanreotide autogel/depot in advanced enteropancreatic neuroendocrinetumours: final results of the CLARINET open-label extension study. Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P; CLARINET Investigators. Endocrine. 2021 Feb;71(2):502-513. doi: 10.1007/s12020-020-02475-2. Epub 2020 Oct 14. PMID: 33052555

• Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial. Rinke A, Neary MP, Eriksson J, Hunger M, Doan T, Karli D, Arnold R. Neuroendocrinology. 2019;109(2):141-151. doi: 10.1159/000499469. Epub 2019 Mar 11. PMID: 30852564

• Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R; PROMID Study Group. Neuroendocrinology. 2017;104(1):26-32. doi: 10.1159/000443612. Epub 2016 Jan 6. PMID: 26731483

• Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrinetumours: the CLARINET open-label extension study. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490. Epub 2016 Jan 7. PMID: 26743120

• Lanreotide in metastatic enteropancreatic neuroendocrine tumors. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. PMID: 25014687

• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. PMID: 19704057

• Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. Neuroendocrinology. 2022;112(3):298-310. doi: 10.1159/000516958. Epub 2021 May 3. PMID: 33940581

• Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Clin Ther. 2021 Oct;43(10):1779-1785. doi: 10.1016/j.clinthera.2021.08.014. Epub 2021 Sep 28. PMID: 34598813

• Time to Sustained Improvement in Bowel Movement Frequency with TelotristatEthyl: Analyses of Phase III Studies in Carcinoid Syndrome. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. J Gastrointest Cancer. 2021 Mar;52(1):212-221. doi: 10.1007/s12029-020-00375-2. PMID: 32146619

• Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECASTphase 3 trial. Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R. Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12. PMID: 29330194

• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. J Clin Oncol. 2017 Jan;35(1):14-23. doi: 10.1200/JCO.2016.69.2780. Epub 2016 Oct 28. PMID: 27918724

• [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203

• (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718

• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7. PMID: 29878866

• Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709

• Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Ann Oncol. 2019 Dec 1;30(12):2010. doi: 10.1093/annonc/mdz222. PMID: 31406974

• Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Pavel ME, Baudin E, Öberg KE, Hainsworth JD, Voi M, Rouyrre N, Peeters M, Gross DJ, Yao JC. Ann Oncol. 2017 Jul 1;28(7):1569-1575. doi: 10.1093/annonc/mdx193. PMID: 28444114

• Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K. J Clin Oncol. 2016 Nov 10;34(32):3906-3913. doi: 10.1200/JCO.2016.68.0702. Epub 2016 Sep 30. PMID: 27621394

• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17. PMID: 26703889

• Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group. Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25. PMID: 22119496

• Everolimus for advanced pancreatic neuroendocrine tumors. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. PMID: 21306238

• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E. Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561. PMID: 27836885

• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. N Engl J Med. 2011 Feb 10;364(6):501-13. doi: 10.1056/NEJMoa1003825. PMID: 21306237

• Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. N Engl J Med. 2024 Sep 16. doi: 10.1056/NEJMoa2403991. Online ahead of print. PMID: 39282913

• Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20. PMID: 32966811

• Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Lancet Oncol. 2020 Nov;21(11):1489-1499. doi: 10.1016/S1470-2045(20)30493-9. Epub 2020 Sep 20. PMID: 32966810

• Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS.J Clin Oncol. 2017 May 20;35(15):1695-1703. doi: 10.1200/JCO.2016.70.4072. Epub 2017 Apr 6. PMID: 28384065

• Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version. PDQ Adult Treatment Editorial Board. 2024 Sep 19. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389233
• Pediatric Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®): Health Professional Version. PDQ Pediatric Treatment Editorial Board. 2024 Sep 13. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 31661208
• Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Health Professional Version. PDQ Adult Treatment Editorial Board. 2024 Aug 16. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389309
• Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version. PDQ Cancer Genetics Editorial Board. 2024 Jun 12. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389271

• Gastrointestinal Neuroendocrine Tumors Treatment (PDQ): Patient Version. PDQ Adult Treatment Editorial Board. 2023 Jun 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389212

• Childhood Gastrointestinal Neuroendocrine Tumors Treatment (PDQ): Patient Version. PDQ Pediatric Treatment Editorial Board. 2022 Dec 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 31661205

• Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ): Patient Version. PDQ Adult Treatment Editorial Board. 2022 Oct 7. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002–. PMID: 26389340

• ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging. Ebner R, Sheikh GT, Brendel M, Ricke J, Cyran CC. Eur Radiol. 2024 Oct 10. doi: 10.1007/s00330-024-11095-7. Online ahead of print. PMID: 39387873

• Clinical Practice Guideline: Recommendations for the Perioperative Management of Pancreatic and Colorectal Cancer Patients. Vilz TO, Post S, Langer T, Follmann M, Nothacker M, Willis MA; the POMGAT Guideline Group. Dtsch Arztebl Int. 2024 Oct 4;(Forthcoming):arztebl.m2024.0172. doi: 10.3238/arztebl.m2024.0172. Online ahead of print. PMID: 39189068

• Surgery for advanced pancreatic neuroendocrine neoplasms: recommendations based on a consensus meeting of the European Society of Endocrine Surgeons (ESES). Van Beek DJ, Van Den Heede K, Borel Rinkes I, Norlén O, Van Slycke S, Stålberg P, Nordenström E. Br J Surg. 2024 Jan 31;111(2):znae017. doi: 10.1093/bjs/znae017. PMID: 38364061

• International consensus guidelines on robotic pancreatic surgery in 2023. Liu R, Abu Hilal M, Besselink MG, Hackert T, Palanivelu C, Zhao Y, He J, Boggi U, Jang JY, Panaro F, Goh BKP, Efanov M, Nagakawa Y, Kim HJ, Yin X, Zhao Z, Shyr YM, Iyer S, Kakiashvili E, Han HS, Lee JH, Croner R, Wang SE, Marino MV, Prasad A, Wang W, He S, Yang K, Liu Q, Wang Z, Li M, Xu S, Wei K, Deng Z, Jia Y, van Ramshorst TME. Hepatobiliary Surg Nutr. 2024 Feb 1;13(1):89-104. doi: 10.21037/hbsn-23-132. Epub 2024 Jan 18. PMID: 38322212

• The Brescia Internationally Validated European Guidelines on Minimally Invasive Pancreatic Surgery (EGUMIPS). Abu Hilal M, van Ramshorst TME, Boggi U, Dokmak S, Edwin B, Keck T, Khatkov I, Ahmad J, Al Saati H, Alseidi A, Azagra JS, Björnsson B, Can FM, D'Hondt M, Efanov M, Espin Alvarez F, Esposito A, Ferrari G, Groot Koerkamp B, Gumbs AA, Hogg ME, Huscher CGS, Ielpo B, Ivanecz A, Jang JY, Liu R, Luyer MDP, Menon K, Nakamura M, Piardi T, Saint-Marc O, White S, Yoon YS, Zerbi A, Bassi C, Berrevoet F, Chan C, Coimbra FJ, Conlon KCP, Cook A, Dervenis C, Falconi M, Ferrari C, Frigerio I, Fusai GK, De Oliveira ML, Pinna AD, Primrose JN, Sauvanet A, Serrablo A, Smadi S, Badran A, Baychorov M, Bannone E, van Bodegraven EA, Emmen AMLH, Giani A, de Graaf N, van Hilst J, Jones LR, Levi Sandri GB, Pulvirenti A, Ramera M, Rashidian N, Sahakyan MA, Uijterwijk BA, Zampedri P, Zwart MJW, Alfieri S, Berti S, Butturini G, Di Benedetto F, Ettorre GM, Giuliante F, Jovine E, Memeo R, Portolani N, Ruzzenente A, Salvia R, Siriwardena AK, Besselink MG, Asbun HJ; Collaborators. Ann Surg. 2024 Jan 1;279(1):45-57. doi: 10.1097/SLA.0000000000006006. Epub 2023 Jul 14. PMID: 37450702

  
  

• Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM). Panzuto F, Albertelli M, De Rimini ML, Rizzo FM, Grana CM, Cives M, Faggiano A, Versari A, Tafuto S, Fazio N, Colao A, Scalorbi F, Ferone D, Cinieri S, Maccauro M. J Endocrinol Invest. 2024 Oct 12. doi: 10.1007/s40618-024-02448-6. Online ahead of print. PMID: 39395114 Review.

• Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety. Malandrino P, Feola T, Mikovic N, Cannavale G, Molfetta SD, Altieri B, Mancini C, Ferolla P, Colao A, Faggiano A; NIKE Group. Semin Nucl Med. 2024 Jul;54(4):570-580. doi: 10.1053/j.semnuclmed.2024.05.001. Epub 2024 May 28. PMID: 38811266
• [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203
• Use and perceived utility of [(18) F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. J Neuroendocrinol. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. PMID: 38097193
• Incidental 68Ga-DOTATATE uptake in thyroid nodules: Is guideline-directed management still appropriate? Wright K, Fisher JC, Rothberger GD, Prescott JD, Allendorf JD, Patel K, Suh I. Surgery. 2024 Jan;175(1):228-233. doi: 10.1016/j.surg.2023.04.064. Epub 2023 Oct 28. PMID: 38563428

• SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taïeb D, Kjaer A. J Nucl Med. 2023 Feb;64(2):204-210. doi: 10.2967/jnumed.122.264860. PMID: 36725249

• ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. Clin Nucl Med. 2022 Jun 1;47(6):503-511. doi: 10.1097/RLU.0000000000004182. PMID: 35507433

• Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Herrmann K, Giovanella L, Santos A, Gear J, Ozgen Kiratli P, Kurth J, Denis-Bacelar AM, Hustinx R, Patt M, Wahl RL, Paez D, Giammarile F, Jadvar H, Pandit-Taskar N, Ghesani M, Kunikowska J. J Nucl Med. 2022 Dec;63(12):1836-1843. doi: 10.2967/jnumed.122.264321. Epub 2022 Apr 21. PMID: 35450957

• NANETS/SNMMIConsensus Statement on Patient Selection and Appropriate Use of (177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy. Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. J Nucl Med. 2020 Feb;61(2):222-227. doi: 10.2967/jnumed.119.240911. PMID: 32015164

• NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. J Nucl Med. 2019 Jul;60(7):937-943. doi: 10.2967/jnumed.118.230607. PMID: 31263080

• [Somatostatin receptor PET/CT (SSTR-PET/CT)]. Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A. Nuklearmedizin. 2018 Feb;57(1):4-17. German. doi: 10.1055/s-0038-1636560. Epub 2018 Feb 21. PMID: 29536494
• Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. PMID: 29025982; PMCID: PMC6910630
  

• Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601. doi: 10.1007/s00259-017-3728-y. Epub 2017 May 25. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Aug 30;: PMID: 28547177
• [Selective intraarterial radiotherapy (SIRT) of malignant liver tumors]. Müller SP, Ezziddin S, Antoch G, Lauenstein T, Amthauer H, Haug AR, Bockisch A. Nuklearmedizin. 2017;56(5):162-170. German. doi: 10.3413/Nukmed-2017-05-0001. Epub 2018 Jan 4. PMID: 29533422
  

• [Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]. Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP. Nuklearmedizin. 2015;54(1):1-11; quiz N2. German. PMID: 25683107

• The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):584. O'Dorisiol, T M [corrected to O’Dorisio, T M]. PMID: 23389427; PMCID: PMC3622744

• Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):2004-10. doi: 10.1007/s00259-010-1512-3. PMID: 20596866

• PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J. J Neuroendocrinol. 2024 Sep 7:e13443. doi: 10.1111/jne.13443. Online ahead of print. PMID: 39243213

• [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. PMID: 38851203

• Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm. Trikalinos NA, Kim H, Vijayan A, Amurao M, Prasad V.J Neuroendocrinol. 2024 Jun;36(6):e13393. doi: 10.1111/jne.13393. Epub 2024 Apr 15. PMID: 38622851

• Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Cordero-Hernandez IS, Ross AC, Dasari A, Halperin DM, Chasen B, Yao JC. Endocr Relat Cancer. 2024 Mar 1;31(4):e230203. doi: 10.1530/ERC-23-0203. Print 2024 Apr 1. PMID: 38329269

• The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE. Veerman CHAM, Siebinga H, de Vries-Huizing DMV, Tesselaar MET, Hendrikx JJMA, Stokkel MPM, Aalbersberg EA. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1434-1441. doi: 10.1007/s00259-022-06094-z. Epub 2023 Jan 4. PMID: 36598536

• (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718

• Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Chantadisai M, Kulkarni HR, Baum RP. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1390-1398. doi: 10.1007/s00259-020-05127-9. Epub 2020 Nov 27. PMID: 33247328

• 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Fröss-Baron K, Garske-Roman U, Welin S, Granberg D, Eriksson B, Khan T, Sandström M, Sundin A. Neuroendocrinology. 2021;111(4):330-343. doi: 10.1159/000506746. Epub 2020 Feb 25. PMID: 32097917

• Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11. PMID: 31187162

• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group. J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7. PMID: 29878866

• Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PMID: 28076709

• Immunosuppression protocols for emerging oncological indications in liver transplantation: A systematic review and pooled analysis. Angelico R, Bonaccorsi Riani E, De Martin E, Parente A, Foguenne M, Sensi B, Rodríguez-Perálvarez ML; Liver Transplant Immunology Special Interest Group of the International Liver Transplant Society (ILTS). Liver Transpl. 2024 Oct 1. doi: 10.1097/LVT.0000000000000499. Epub ahead of print. PMID: 39347698

• S2K-Leitlinie Lebertransplantation - AWMF Leitlinienregister
  
• The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors. Citterio D, Coppa J, Sposito C, Busset MDD, Virdis M, Pezzoli I, Mazzaferro V. Curr Treat Options Oncol. 2023 Nov;24(11):1651-1665. doi: 10.1007/s11864-023-01124-w. Epub 2023 Oct 26. PMID: 37882889; PMCID: PMC10643461.
  

• Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Hibi T, Rela M, Eason JD, Line PD, Fung J, Sakamoto S, Selzner N, Man K, Ghobrial RM, Sapisochin G. Transplantation. 2020 Jun;104(6):1131-1135. doi: 10.1097/TP.0000000000003118. PMID: 32217939
  

• Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, Pavel M, Thariat J, van Velthuysen MF, Herman P, Dromain C, Baudin E, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2024 Oct;9(10):103664. doi: 10.1016/j.esmoop.2024.103664. Epub 2024 Oct 1. PMID: 39461777

• Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson ET, Tombal B, Pavel M, Thariat J, van Velthuysen MF, Herman P, Dromain C, Baudin E, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Open. 2024 Oct;9(10):103664. doi: 10.1016/j.esmoop.2024.103664. Epub 2024 Oct 1. PMID: 39461777

• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Endocr Relat Cancer. 2023 Jul 11;30(8):e220206. doi: 10.1530/ERC-22-0206. PMID: 37184955; PMCID: PMC10388681 
  

• Neuroendocrine tumors of the gynecologic tract update. Winer I, Kim C, Gehrig P. Gynecol Oncol. 2021 Jul;162(1):210-219. doi: 10.1016/j.ygyno.2021.04.039. Epub 2021 May 20. PMID: 34023130

• The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME. Epigenomics. 2024;16(17):1129-1132. doi: 10.1080/17501911.2024.2391729. Epub 2024 Sep 3. PMID: 39225130
• Promising therapy for neuroendocrine prostate cancer: current status and future directions.  Fei X, Xue JW, Wu JZ, Yang CY, Wang KJ, Ma Q. Ther Adv Med Oncol. 2024 Aug 8;16:17588359241269676. doi: 10.1177/17588359241269676. PMID: 39131727

• Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. JU Open Plus. 2024 Apr;2(4):e00032. doi: 10.1097/ju9.0000000000000138. Epub 2024 Apr 15. PMID: 38774467

• The Current Therapeutic Landscape for Metastatic Prostate Cancer. Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G. Pharmaceuticals (Basel). 2024 Mar 8;17(3):351. doi: 10.3390/ph17030351. PMID: 38543137 Free PMC article. Review 

• Diagnosis and management of neuroendocrine prostate cancer. de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. Prostate. 2024 Jan 3. doi: 10.1002/pros.24664. Epub ahead of print. PMID: 38173302
  

• Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, Miyamoto H. Anticancer Res. 2023 Sep;43(9):3841-3847. doi: 10.21873/anticanres.16571. PMID: 37648316 Review.

• Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. PMID: 30713600; PMCID: PMC6343754
  

• Recurrence Rates and Patterns after Radical Resection of Lung Carcinoids. Askildsen E, Soldath P, Langer SW, Andreassen M, Knigge U, Petersen RH. Cancers (Basel). 2024 Aug 27;16(17):2978. doi: 10.3390/cancers16172978. PMID: 39272839
• Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force. Koumarianou A, Filosso PL, Bodei L, Castano JP, Fernandez-Cuesta L, Deroose CM, Foll M, Dromain C, Reed NS, Caplin M, Capdevila J, Falkerby J, Faggiano A, Frilling A, Grande E, Hicks RJ, Kasajima A, Kos-Kudla B, Krishna BA, Lim E, Rinke A, Singh S, Thirlwell C, Volante M, Walter T. J Neuroendocrinol. 2024 Aug;36(8):e13412. doi: 10.1111/jne.13412. Epub 2024 May 16. PMID: 38754956
• Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety. Malandrino P, Feola T, Mikovic N, Cannavale G, Molfetta SD, Altieri B, Mancini C, Ferolla P, Colao A, Faggiano A; NIKE Group. Semin Nucl Med. 2024 Jul;54(4):570-580. doi: 10.1053/j.semnuclmed.2024.05.001. Epub 2024 May 28. PMID: 38811266

• Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms. Dam G, Grønbæk H, Sundlöv A, Botling J, Sundin A, Petersen RH, Welin S, Evensen ET, Sorbye H, Tabaksblat E, Arveschoug AK, Mortensen J, Kjaer A, Knigge U, Tiensuu Janson E, Langer SW. Acta Oncol. 2023 May;62(5):431-437. doi: 10.1080/0284186X.2023.2212411. Epub 2023 May 16. PMID: 37194281
  

• Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Ann Oncol. 2021 Apr;32(4):439-451. doi: 10.1016/j.annonc.2021.01.003. Epub 2021 Jan 19. Erratum in: Ann Oncol. 2021 Nov;32(11):1453-1455. PMID: 33482246

• Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. J Thorac Oncol. 2020 Oct;15(10):1577-1598. doi: 10.1016/j.jtho.2020.06.021. Epub 2020 Jul 11. PMID: 32663527

• Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. Das S, Stockton SS, Hassan SA. Oncologist. 2023 Jul 5;28(7):575-583. doi: 10.1093/oncolo/oyad126. PMID: 37209415
• Carcinoid heart disease in patients with midgut neuroendocrine tumours. Delhomme C, Walter T, Arangalage D, Suc G, Hentic O, Cachier A, Alkhoder S, François L, Lombard-Bohas C, Iung B, Ruszniewski P, de Mestier L. J Neuroendocrinol. 2023 Apr;35(4):e13262. doi: 10.1111/jne.13262. Epub 2023 Apr 2. PMID: 37005217

• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Erratum in: Eur Heart J. 2023 May 7;44(18):1621. doi: 10.1093/eurheartj/ehad196. PMID: 36017568
• European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Albåge A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111/jne.13146. Epub 2022 May 25. PMID: 35613326
• Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease Task Force). Hofland J, Lamarca A, Steeds R, Toumpanakis C, Srirajaskanthan R, Riechelmann R, Panzuto F, Frilling A, Denecke T, Christ E, Grozinsky-Glasberg S, Davar J; ENETS Carcinoid Heart Disease Task Force. J Neuroendocrinol. 2022 Mar;34(3):e13060. doi: 10.1111/jne.13060. Epub 2021 Nov 26. PMID: 34825753

• French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d'étude des Tumeurs Endocrines / Association Française de Chirurgie Endocrinienne / REseau NAtional de prise en charge des Tumeurs ENdocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1. Goudet P, Cadiot G, Barlier A, Baudin E, Borson-Chazot F, Brunaud L, Caiazzo R, Cardot-Bauters C, Castinetti F, Chanson P, Cuny T, Dansin E, Gaujoux S, Giraud S, Groussin L, Bras ML, Lifante JC, Mathonnet M, de Mestier L, Mirallié E, Pattou F, Romanet P, Sebag F, Tresallet C, Vezzosi D, Walter T, Tabarin A. Ann Endocrinol (Paris). 2023 Sep 20:S0003-4266(23)00707-2. doi: 10.1016/j.ando.2023.09.003. Online ahead of print. PMID: 37739121 Review. No abstract available.

• Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Niederle B, Selberherr A, Bartsch DK, Brandi ML, Doherty GM, Falconi M, Goudet P, Halfdanarson TR, Ito T, Jensen RT, Larghi A, Lee L, Öberg K, Pavel M, Perren A, Sadowski SM, Tonelli F, Triponez F, Valk GD, O'Toole D, Scott-Coombes D, Thakker RV, Thompson GB, Treglia G, Wiedenmann B. Neuroendocrinology. 2021;111(7):609-630. doi: 10.1159/000511791. Epub 2020 Sep 24. PMID: 32971521

• Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML; Endocrine Society. J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011. doi: 10.1210/jc.2012-1230. Epub 2012 Jun 20. PMID: 22723327

• Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J; International VHL Surveillance Guidelines Consortium. Cancer. 2023 Jun 19. doi: 10.1002/cncr.34896. Epub ahead of print. PMID: 37337409

• Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A; Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Cancer. 2022 Feb 1;128(3):435-446. doi: 10.1002/cncr.33978. Epub 2021 Nov 4. PMID: 34735022

• Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement. Huntoon K, Shepard MJ, Lukas RV, McCutcheon IE, Daniels AB, Asthagiri AR. J Neurosurg. 2021 Oct 1;136(6):1511-1516. doi: 10.3171/2021.3.JNS204203. PMID: 34598132

• Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Binderup ML, Bisgaard ML, Harbud V, Møller HU, Gimsing S, Friis-Hansen L, Hansen Tv, Bagi P, Knigge U, Kosteljanetz M, Bøgeskov L, Thomsen C, Gerdes AM, Ousager LB, Sunde L; Danish vHL Coordination Group. Dan Med J. 2013 Dec;60(12):B4763. PMID: 24355456

• ERN GENTURIS NF1 Tumour Management Guideline Group. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, Röhl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R. EClinicalMedicine. 2023 Jan 13;56:101818. doi: 10.1016/j.eclinm.2022.101818. PMID: 36684394; PMCID: PMC9845795
  

• Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Merker VL, Knight P, Radtke HB, Yohay K, Ullrich NJ, Plotkin SR, Jordan JT. Orphanet J Rare Dis. 2022 Feb 10;17(1):44. doi: 10.1186/s13023-022-02196-x. PMID: 35144646; PMCID: PMC8832755

• Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC); Huson SM, Evans DG, Plotkin SR. Genet Med. 2021 Aug;23(8):1506-1513. doi: 10.1038/s41436-021-01170-5. Epub 2021 May 19. PMID: 34012067; PMCID: PMC8354850

• Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P; NF France Network. Orphanet J Rare Dis. 2020 Feb 3;15(1):37. doi: 10.1186/s13023-020-1310-3. PMID: 32014052; PMCID: PMC6998847

• Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Genet Med. 2018 Jul;20(7):671-682. doi: 10.1038/gim.2018.28. Epub 2018 Apr 26. PMID: 30006586

• The Optimal Approach to Surgical Management of Goblet Cell Carcinoid of the Appendix: A Systematic Review. Salama MM, O'Neill MA, Ryan ÉJ, O'Sullivan NJ, Nugent TS, Temperley HC, Mehigan BJ, Larkin JO, Gallagher D, O'Kane G, McCormick PH, Kelly ME. Diagnostics (Basel). 2024 Aug 14;14(16):1773. doi: 10.3390/diagnostics14161773. PMID: 39202258

• Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry. Palmer K, Weerasuriya S, Chandrakumaran K, Rous B, White BE, Paisey S, Srirajaskanthan R, Ramage JK. Front Oncol. 2022 Jul 12;12:915028. doi: 10.3389/fonc.2022.915028. PMID: 35903705

• Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Govaerts K, Lurvink RJ, De Hingh IHJT, Van der Speeten K, Villeneuve L, Kusamura S, Kepenekian V, Deraco M, Glehen O, Moran BJ; PSOGI. Eur J Surg Oncol. 2021 Jan;47(1):11-35. doi: 10.1016/j.ejso.2020.02.012. Epub 2020 Feb 28. PMID: 32199769

• The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Chicago Consensus Working Group. Ann Surg Oncol. 2020 Jun;27(6):1788-1792. doi: 10.1245/s10434-020-08321-z. Epub 2020 Apr 13. PMID: 32285274

Lymph node metastases are more frequent in paediatric appendiceal NET ≥1.5 cm but without impact on outcome - Data from the German MET studies. Kuhlen M, Kunstreich M, Pape UF, Seitz G, Lessel L, Vokuhl C, Frühwald MC, Vorwerk P, Redlich A. Eur J Surg Oncol. 2024 Apr;50(4):108051. doi: 10.1016/j.ejso.2024.108051. Epub 2024 Feb 27. PMID: 38430702

Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study. Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, Brcic I, Brunner M, Cadiot G, Camara M, Christ E, Clerici T, Clift AK, Clouston H, Cobianchi L, Ćwikła JB, Daskalakis K, Frilling A, Garcia-Carbonero R, Grozinsky-Glasberg S, Hernando J, Hervieu V, Hofland J, Holmager P, Inzani F, Jann H, Jimenez-Fonseca P, Kaçmaz E, Kaemmerer D, Kaltsas G, Klimacek B, Knigge U, Kolasińska-Ćwikła A, Kolb W, Kos-Kudła B, Kunze CA, Landolfi S, La Rosa S, López CL, Lorenz K, Matter M, Mazal P, Mestre-Alagarda C, Del Burgo PM, van Dijkum EJMN, Oleinikov K, Orci LA, Panzuto F, Pavel M, Perrier M, Reims HM, Rindi G, Rinke A, Rinzivillo M, Sagaert X, Satiroglu I, Selberherr A, Siebenhüner AR, Tesselaar MET, Thalhammer MJ, Thiis-Evensen E, Toumpanakis C, Vandamme T, van den Berg JG, Vanoli A, van Velthuysen MF, Verslype C, Vorburger SA, Lugli A, Ramage J, Zwahlen M, Perren A, Kaderli RM. Lancet Oncol. 2023 Feb;24(2):187-194. doi: 10.1016/S1470-2045(22)00750-1. Epub 2023 Jan 11. PMID: 36640790

• Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients. Lussey-Lepoutre C, Pacak K, Grossman A, Taieb D, Amar L. Best Pract Res Clin Endocrinol Metab. 2024 Sep 7:101938. doi: 10.1016/j.beem.2024.101938. Online ahead of print. PMID: 39271377

• International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Casey RT, Hendriks E, Deal C, Waguespack SG, Wiegering V, Redlich A, Akker S, Prasad R, Fassnacht M, Clifton-Bligh R, Amar L, Bornstein S, Canu L, Charmandari E, Chrisoulidou A, Freixes MC, de Krijger R, de Sanctis L, Fojo A, Ghia AJ, Huebner A, Kosmoliaptsis V, Kuhlen M, Raffaelli M, Lussey-Lepoutre C, Marks SD, Nilubol N, Parasiliti-Caprino M, Timmers HHJLM, Zietlow AL, Robledo M, Gimenez-Roqueplo AP, Grossman AB, Taïeb D, Maher ER, Lenders JWM, Eisenhofer G, Jimenez C, Pacak K, Pamporaki C. Nat Rev Endocrinol. 2024 Aug 15. doi: 10.1038/s41574-024-01024-5. Online ahead of print. PMID: 39147856

• Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants. Taïeb D, Wanna GB, Ahmad M, Lussey-Lepoutre C, Perrier ND, Nölting S, Amar L, Timmers HJLM, Schwam ZG, Estrera AL, Lim M, Pollom EL, Vitzthum L, Bourdeau I, Casey RT, Castinetti F, Clifton-Bligh R, Corssmit EPM, de Krijger RR, Del Rivero J, Eisenhofer G, Ghayee HK, Gimenez-Roqueplo AP, Grossman A, Imperiale A, Jansen JC, Jha A, Kerstens MN, Kunst HPM, Liu JK, Maher ER, Marchioni D, Mercado-Asis LB, Mete O, Naruse M, Nilubol N, Pandit-Taskar N, Sebag F, Tanabe A, Widimsky J, Meuter L, Lenders JWM, Pacak K. Lancet Diabetes Endocrinol. 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31. PMID: 37011647; PMCID: PMC10182476
  

• Personalized Management of Pheochromocytoma and Paraganglioma. Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Endocr Rev. 2022 Mar 9;43(2):199-239. doi: 10.1210/endrev/bnab019. Erratum in: Endocr Rev. 2021 Dec 14;: Erratum in: Endocr Rev. 2021 Dec 14;: PMID: 34147030; PMCID: PMC8905338
  
• Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Mete, O., Asa, S.L., Gill, A.J. et al. Endocr Pathol 33, 90–114 (2022). https://doi.org/10.1007/s12022-022-09704-6
  

• International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, Buffet A, Burnichon N, Clifton-Bligh RJ, Dahia PLM, Fassnacht M, Grossman AB, Herman P, Hicks RJ, Januszewicz A, Jimenez C, Kunst HPM, Lewis D, Mannelli M, Naruse M, Robledo M, Taïeb D, Taylor DR, Timmers HJLM, Treglia G, Tufton N, Young WF, Lenders JWM, Gimenez-Roqueplo AP, Lussey-Lepoutre C. Nat Rev Endocrinol. 2021 Jul;17(7):435-444. doi: 10.1038/s41574-021-00492-3. Epub 2021 May 21. PMID: 34021277

• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. Pancreas. 2021 Apr 1;50(4):469-493. doi: 10.1097/MPA.0000000000001792. PMID: 33939658

• European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29. PMID: 31254038; PMCID: PMC7446938
• Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK). Lorenz K, Langer P, Niederle B, Alesina P, Holzer K, Nies C, Musholt T, Goretzki PE, Rayes N, Quinkler M, Waldmann J, Simon D, Trupka A, Ladurner R, Hallfeldt K, Zielke A, Saeger D, Pöppel T, Kukuk G, Hötker A, Schabram P, Schopf S, Dotzenrath C, Riss P, Steinmüller T, Kopp I, Vorländer C, Walz MK, Bartsch DK. Langenbecks Arch Surg. 2019 Jun;404(4):385-401. doi: 10.1007/s00423-019-01768-z. Epub 2019 Apr 1. PMID: 30937523
  

• European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, Lussey-Lepoutre C, Steichen O; Guideline Working Group. Eur J Endocrinol. 2016 May;174(5):G1-G10. doi: 10.1530/EJE-16-0033. PMID: 27048283

• Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. Erratum in: J Clin Endocrinol Metab. 2023 Apr 13;108(5):e200. PMID: 24893135

• Diagnosis, Management, and Follow-Up of the Incidentally Discovered Adrenal Mass: CUA Guideline Endorsed by the AUA. Rowe NE, Kumar R, Schieda N, Siddiqi F, McGregor T, McAlpine K, Violette P, Bathini V, Eng M, Izard J.J Urol. 2023 Oct;210(4):590-599. doi: 10.1097/JU.0000000000003644. Epub 2023 Aug 9. PMID: 37556768

• European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM.Eur J Endocrinol. 2023 Jul 20;189(1):G1-G42. doi: 10.1093/ejendo/lvad066. PMID: 37318239

• American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C, Velázquez-Fernández D, Berber E, Hammer GD, Bancos I, Lee JA, Marko J, Morris-Wiseman LF, Hughes MS, Livhits MJ, Han MA, Smith PW, Wilhelm S, Asa SL, Fahey TJ 3rd, McKenzie TJ, Strong VE, Perrier ND. JAMA Surg. 2022 Oct 1;157(10):870-877. doi: 10.1001/jamasurg.2022.3544. PMID: 35976622

• Consensus on diagnosis and management of Cushing's disease: a guideline update. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. PMID: 34687601; PMCID: PMC8743006

• Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK). Lorenz K, Langer P, Niederle B, Alesina P, Holzer K, Nies C, Musholt T, Goretzki PE, Rayes N, Quinkler M, Waldmann J, Simon D, Trupka A, Ladurner R, Hallfeldt K, Zielke A, Saeger D, Pöppel T, Kukuk G, Hötker A, Schabram P, Schopf S, Dotzenrath C, Riss P, Steinmüller T, Kopp I, Vorländer C, Walz MK, Bartsch DK. Langenbecks Arch Surg. 2019 Jun;404(4):385-401. doi: 10.1007/s00423-019-01768-z. Epub 2019 Apr 1. PMID: 30937523

• Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A; Endocrine Society. J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29. PMID: 26222757; PMCID: PMC4525003

• Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis. Chen J, Ye J, Zheng X, Chen J. J Gastrointest Surg. 2024 Mar;28(3):301-308. doi: 10.1016/j.gassur.2023.12.016. Epub 2024 Jan 23. PMID: 38445925

• Endoscopic and Surgical Management of Non-Metastatic Ampullary Neuroendocrine Neoplasia: A Multi-Institutional Pancreas2000/EPC Study. Karam E, Hollenbach M, Abou Ali E, Auriemma F, Anderloni A, Barbier L, Belfiori G, Caillol F, Crippa S, Del Chiaro M, De Ponthaud C, Dahel Y, Falconi M, Giovannini M, Heling D, Inoue Y, Jarnagin WR, Leung G, Lupinacci RM, Mariani A, Masaryk V, Miksch RC, Musquer N, Napoleon B, Oba A, Partelli S, Petrone MC, Prat F, Repici A, Sauvanet A, Salzmann K, Schattner MA, Schulick R, Schwarz L, Soares K, Souche FR, Truant S, Vaillant JC, Wang T, Wedi E, Werner J, Weismüller TJ, Wichmann D, Will U, Zaccari P, Gulla A, Heise C, Regner S, Gaujoux S; Pancreas 2000 Research Group. Neuroendocrinology. 2023;113(10):1024-1034. doi: 10.1159/000531712. Epub 2023 Jun 27. PMID: 37369186

• Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Deprez PH, Moons LMG, OʼToole D, Gincul R, Seicean A, Pimentel-Nunes P, Fernández-Esparrach G, Polkowski M, Vieth M, Borbath I, Moreels TG, Nieveen van Dijkum E, Blay JY, van Hooft JE. Endoscopy. 2022 Apr;54(4):412-429. doi: 10.1055/a-1751-5742. Epub 2022 Feb 18. PMID: 35180797

• Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Eur J Cancer. 2021 Feb;144:200-214. doi: 10.1016/j.ejca.2020.11.037. Epub 2020 Dec 25. PMID: 33370645; PMCID: PMC7836777

• North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. Pancreas. 2020 Jul;49(6):723-728. doi: 10.1097/MPA.0000000000001561. PMID: 32433264; PMCID: PMC7253037